Q32 Bio Inc. — Form 8-K
Filed November 4, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Q32 Bio completed a $200M public offering in July 2026, bringing cash to $289.6M as of September 30, 2026. The company presented SIGNAL-AA Part B results showing 35.3% mean SALT score reduction at Week 36 in 33 patients and robust durability through 16-week off-drug follow-up, with 40% achieving SALT-20 response. Management appointed Jos Trevejo, M.D., Ph.D. as CMO and Ellie Hershberger, Pharm.D. as CDO in September 2026; the company plans to initiate a registration-directed Phase 3 program in severe/very severe alopecia areata in H1 2027 pending Q4 2026 regulatory discussions.
Why this rating
Major capital raise ($200M ≈ 19× market cap) extends runway through Phase 3 topline; positive efficacy/durability data reduces regulatory risk. For $10.4M company, this funding materially changes business trajectory and substantially de-risks advancement to registration trial.
Price action (we called it positive)
at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.